Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Stemtech (STEK) EBITDA (2020 - 2025)

Historic EBITDA for Stemtech (STEK) over the last 6 years, with Q3 2025 value amounting to -$127115.0.

  • Stemtech's EBITDA rose 9436.69% to -$127115.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$145406.0, marking a year-over-year increase of 9896.1%. This contributed to the annual value of -$4.1 million for FY2024, which is 1774.12% up from last year.
  • Stemtech's EBITDA amounted to -$127115.0 in Q3 2025, which was up 9436.69% from $389146.0 recorded in Q2 2025.
  • In the past 5 years, Stemtech's EBITDA ranged from a high of $17.0 million in Q3 2022 and a low of -$24.6 million during Q2 2022
  • Its 5-year average for EBITDA is -$1.6 million, with a median of -$584502.0 in 2021.
  • As far as peak fluctuations go, Stemtech's EBITDA surged by 39392.47% in 2022, and later tumbled by 936169.43% in 2023.
  • Quarter analysis of 5 years shows Stemtech's EBITDA stood at -$584502.0 in 2021, then skyrocketed by 84.14% to -$92699.0 in 2022, then tumbled by 9361.69% to -$8.8 million in 2023, then soared by 104.17% to $365863.0 in 2024, then tumbled by 134.74% to -$127115.0 in 2025.
  • Its EBITDA was -$127115.0 in Q3 2025, compared to $389146.0 in Q2 2025 and -$773300.0 in Q1 2025.